GENE ONLINE|News &
Opinion
Blog

Business Model and Financial Strategy DecisionsLicensing, M&A, partnering, scaling-up, IPO and m

by GeneOnline
Share To
 
 

The pathways are many, the risks are varied, but the choices made early on will be critical to the future success of a growing biotech company. In this session, we have invited industry veterans and heavyweight speakers to advise on making important decisions around business model development and strategy.

Swimming with Sharks: Early Stage Biotechnology Business Models and Financing Strategies

Dr. Carter will give a talk about bioindustry development cycles and introducing the challenges and opportunities for all early-stage companies.

 

Building a Biotechnology Company through Collaboration, Licensing and M&A

Mr. Grady will address why AstraZeneca set up an innovation center in China while most western big pharma retreated. What strategies, pipelines, or disease areas so far and what can we expect from these strategies?

 

Dr. Li is a Venture Partner with Lilly Asia Ventures. He was most recently Executive VP and Global Head of Business Development at BeiGene; prior to that, he was VP of Business Development and Licensing at Merck and Executive Director of External R&D at Amgen. With over 21 years of industry experience, he will be sharing his investment strategy and insights.

 

Dr. McCracken will share his insight regarding Genentech has leveraged academic collaborations, in-licensing, out-licensing, and M&A to discover and bring its innovative medicines to patients.

 

Session organizer:

Online @ BIO Asia-Taiwan, July 23.
15:40-17:10 Taipei Time

 
Don’t miss your chance to join thousands of bioindustry professionals from Asia and around the world at BIO Asia–Taiwan 2020 Online + Live!
BIO Asia-Taiwan 2020 Secretariat

register@taiwanbio.org.tw | www.bioasiataiwan.com | +886-2-7700-3883

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
BIO Asia-Taiwan 2022: Looking for the Exit; Startup Considerations and Strategies
2022-07-28
BIO Asia-Taiwan 2022: Top iPS Cell Technologies at Affordable Prices – Keynote by Nobel Laureate Shinya Yamanaka
2022-07-28
Reinvigorating the Asian Biomedical Ecosystem With BIO Asia-Taiwan 2022
2022-07-26
LATEST
Targeting Metabolism for Noninvasive Multi-Cancer Early Detection Tests
2022-12-08
Moderna’s Personalized Cancer Therapy: The New Transformative Approach to Oncology
2022-12-08
SK Biopharmaceuticals' Partner Angelini Pharma Launches Cenobamate in France
2022-12-08
Relmada Blames ‘Implausible Placebo Results’ on Depression Drug’s Failure Again
2022-12-07
Using Sound Waves to Sort Blood-Based Nanoparticles
2022-12-07
Summit Bets $5 Billion On Akeso’s Bispecific Antibody
2022-12-07
Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood
2022-12-07
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
2023-01-09
JPM Annual Healthcare Meeting 2023
San Francisco, USA
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!